Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Almac Announces Further Expansion and 229 New Jobs

Published: Monday, June 17, 2013
Last Updated: Monday, June 17, 2013
Bookmark and Share
Dual expansion with completion of a new non-GMP drug development facility.

Following the success of one of its key client partnered products, Craigavon-based pharmaceutical company Almac, has announced the commercial manufacturing expansion.

Together with the recent completion of a new non-GMP drug development facility at the Craigavon site this dual expansion represents a total investment of £13.7million, which includes some financial support from Invest Northern Ireland.

Over the next three years up to 229 jobs will be created across both projects.

The product, a laxative drug, which is contract manufactured by Almac, has recorded robust sales growth year on year throughout the UK and Europe.

With existing facilities at full capacity and further demand forecast in a number of new markets Almac decided to focus all production in Northern Ireland with additional equipment and resources in Craigavon.

The investment will deliver blending equipment, an automated packing and integrated cartoning line which will enable high volume bulk commercial manufacturing scheduled to begin in November 2013.

Also at the Craigavon site Almac is experiencing growth through the creation of a new 13,400 square feet formulation development facility and analytical laboratories.

This facility focuses on the development of tablet and capsule formulations for new drugs which are in the early stages of development and which have not yet reached the market.

The new “non-GMP” facility will enable greater speed in formulation and process development, by creating an environment where development work can be progressed quickly and efficiently, free of many of the constraints usually associated with drug manufacturing.

Graeme McBurney, President & Managing Director of the business unit explains, “The laxative product has been a great success in the UK and increasingly in European markets. The marketing and promotion of the product by our contract customer has been very effective and significant growth potential in several new territories such as China has been identified. Centralizing and expanding our production in Craigavon will mean more cost effective manufacturing and optimal quality control and distribution.”

“We are also delighted to see the completion of the new non-GMP facility on site which, alongside Almac’s existing GMP capability, will enable us to operate with improved speed and efficiency in the early stages of projects. This latest addition makes Almac a much more attractive proposition to international clients who seek streamlined, one stop drug development solutions.”

Enterprise Minister Arlene Foster said, “This investment is good news for Craigavon and will reinforce Northern Ireland’s position in the wider life sciences sector. The 229 new jobs will deliver almost £5.5 million annually in salaries, bringing an important and positive economic boost which will benefit local people.”

“Almac has a reputation for excellence in the international pharmaceuticals sector and today’s announcement will ensure that it remains in a competitive position and can continue to meet the needs of its global client base.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Group Addresses Industry Demand For Multiparticulate Drug Products
In response to increasing client demand for multiparticulate drug delivery systems, Almac Group is providing fluid-bed processing and encapsulation services to its global partners from its UK development and commercial manufacturing facilities.
Monday, October 12, 2015
Almac Addresses Industry Demand for Multiparticulate Drug Products
Company is providing scalable fluid bed and encapsulation technologies to its global partners.
Friday, October 09, 2015
Almac Group Expands Asia Pacific Presence
Company opens new regional headquarters and clinical trial supply facility in Singapore.
Thursday, July 16, 2015
Novozymes Biopharma Announces Collaboration with Almac
Combined service offers drug development companies efficiencies in time and resource.
Tuesday, October 22, 2013
Almac Expands US & UK Commercial Facilities
Investments of over $20m enhance Almac’s commercial facilities on both sides of the Atlantic.
Tuesday, October 22, 2013
Almac Launches US Commercial Packaging Operations in Audubon
Company also announces launch of new client partnership.
Monday, May 20, 2013
Almac Receives FDA Inspection Approval
Successful inspection of analytical facilities at Almac’s Craigavon Headquarters, Northern Ireland from the US FDA.
Thursday, February 21, 2013
Almac Doubles Drug Product Development Capacity with a New Non-GMP Facility
New facility offers clients greater flexibility and speed in formulation and process development.
Tuesday, January 15, 2013
Almac and TTP Labtech form Alliance in Fluorescence Lifetime Technology
This will give customers of either party access to a broad range of biological applications coupled with the next generation of microplate reader technology.
Tuesday, January 08, 2013
Charlie Morris Appointed to Almac’s Clinical Technologies Executive Team
Mr. Morris joins Almac as Vice President of new products and services.
Thursday, December 13, 2012
Almac Concludes Commercial API Manufacturing Facility Expansion Plans
Almac’s expansion is near completion and will be operational by the end of the year.
Tuesday, October 09, 2012
Almac Expands UK Commercial Capacity
Acquisition of new Noack N 623 blister packaging line from Romaco.
Friday, October 05, 2012
Almac Installs Uhlmann Blister Line in New US Commercial Packaging Facility
Acquisition of a high-speed blister line in Audubon, PA.
Monday, July 02, 2012
Almac Introduces QP Facilitation Programme for Conducting Trials in the European Union
Programme vastly simplifies and expedites the QP release process.
Thursday, June 14, 2012
Almac and VTU Technology Form Collaboration
Approach enables homogenous labelled product with retained biological activity.
Tuesday, June 12, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos